Transfusion Reactions

  • Adriana Maria Knopfelmacher
Reference work entry


The use of altruistic donors, the testing for known infectious agents, and other measures have made blood a very safe product. Thus the risk of acquiring an infectious agent by transfusion of blood components has been largely reduced, and the greatest risk in morbidity and mortality following transfusion of blood is due mostly to its noninfectious complications. Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the most commonly reported causes of mortality involving transfusion of blood. Other transfusion reactions such as mild allergic reactions and febrile non-hemolytic transfusion reactions are not lethal but are very common and may produce discomfort and anxiety in the patient.


Complications of transfusion Transfusion reactions TRALI TACO Febrile non-hemolytic transfusion reactions Allergic reactions Acute hemolytic transfusion reaction 


  1. 1.
    Berseus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion. 2013;53(Suppl 1):114S–23S.CrossRefGoogle Scholar
  2. 2.
    Cid J. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review. Vox Sang. 2017;112:607–13.CrossRefGoogle Scholar
  3. 3.
    Crookston KP, Delaney M. In: Crookston KP, Delaney M, editors. Blood transfusion therapy: a physician’s handbook. Bethesda: AABB; 2017. p. 221–47.Google Scholar
  4. 4.
    Cyr M, Hume HA, Champagne M, Sweeney JD, Blais C Jr, Gervais N, Adam A. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion. 1999;39:1084–8.CrossRefGoogle Scholar
  5. 5.
    Davenport RD, Burdick M, Moore SA, Kunkel SL. Cytokine production in IgG-mediated red cell incompatibility. Transfusion. 1993;33:19–24.CrossRefGoogle Scholar
  6. 6.
    Driscoll DF, Bistrian BR, Jenkins RL, Randall S, Dzik WH, Gerson B, Blackburn GL. Development of metabolic alkalosis after massive transfusion during orthotopic liver transplantation. Crit Care Med. 1987;15:905–8.CrossRefGoogle Scholar
  7. 7.
    Dunbar NM, Walsh SJ, Maynard KJ, Szczepiorkowski ZM. Transfusion reaction reporting in the era of hemovigilance: where form meets function. Transfusion. 2011;51:2583–7.CrossRefGoogle Scholar
  8. 8.
    Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2:76–94.CrossRefGoogle Scholar
  9. 9.
    Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ, American Red Cross Regional Blood, C. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004–2006). Transfusion. 2007;47:1134–42.CrossRefGoogle Scholar
  10. 10.
    Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015;55 Suppl 2(0):S47–58.Google Scholar
  11. 11.
    Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007;21:1–12.CrossRefGoogle Scholar
  12. 12.
    Hod E, Savage WJ. In: Eder AF, Fung MK, Spitalnik S, Westhoff CM, editors. Technical manual 19th edition. AABB; 2017. p. 569–98.Google Scholar
  13. 13.
    Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994;331:625–8.CrossRefGoogle Scholar
  14. 14.
    Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman J L. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program. 2003;575–89.Google Scholar
  15. 15.
    Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.CrossRefGoogle Scholar
  16. 16.
    Janssen MP, Van Tilborgh AJW, De Vooght KMK, Bokhorst AG, Wiersum-Osselton JC. Direct costs of transfusion reactions – an expert judgement approach. Vox Sang. 2018;113:143–51.CrossRefGoogle Scholar
  17. 17.
    Kaufman RM, Assmann SF, Triulzi DJ, Strauss RG, Ness P, Granger S, Slichter SJ. Transfusion-related adverse events in the Platelet Dose study. Transfusion. 2015;55:144–53.CrossRefGoogle Scholar
  18. 18.
    Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17:120–62.CrossRefGoogle Scholar
  19. 19.
    Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44:1774–89.CrossRefGoogle Scholar
  20. 20.
    Kohan AI, Niborski RC, Rey JA, Amerise G, Vazquez MI, Zani N, Calahonra R, Binaghi A, Sanchez Avalos J. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang. 1994;67:195–8.CrossRefGoogle Scholar
  21. 21.
    Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev. 1992;6:116–23.CrossRefGoogle Scholar
  22. 22.
    Moroff G, Leitman SF, Luban NL. Principles of blood irradiation, dose validation, and quality control. Transfusion. 1997;37:1084–92.CrossRefGoogle Scholar
  23. 23.
    Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52:160–5.CrossRefGoogle Scholar
  24. 24.
    Sapiano MRP, Savinkina AA, Ellingson KD, Haass KA, Baker ML, Henry RA, Berger JJ, Kuehnert MJ, Basavaraju SV. Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015. Transfusion. 2017;57:1599–624.CrossRefGoogle Scholar
  25. 25.
    Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med. 1993;328:766–70.CrossRefGoogle Scholar
  26. 26.
    Shtalrid M, Shvidel L, Vorst E, Weinmann EE, Berrebi A, Sigler E. Post-transfusion purpura: a challenging diagnosis. Isr Med Assoc J. 2006;8:672–4.PubMedGoogle Scholar
  27. 27.
    Stowell SR, Winkler AM, Maier CL, Arthur CM, Smith NH, Girard-Pierce KR, Cummings RD, Zimring JC, Hendrickson JE. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol. 2012;2012:307093.CrossRefGoogle Scholar
  28. 28.
    Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47:1089–96.CrossRefGoogle Scholar
  29. 29.
    Tobian AA, Fuller AK, Uglik K, Tisch DJ, Borge PD, Benjamin RJ, Ness PM, King KE. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion. 2014;54:1523–9.. quiz 1522CrossRefGoogle Scholar
  30. 30.
    U.S. Centers for Disease Control and Prevention. 2018. The National Healthcare Safety Network (NHSN) manual: biovigilance components v2.5. [Online]. Atlanta: Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases. Available:. Accessed 07 Dec 2018.
  31. 31.
    US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for Fiscal year 2016. [Online]. 2016. Available: Accessed 22 Apr 2018.
  32. 32.
    Wang RR, Triulzi DJ, Qu L. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets. Am J Clin Pathol. 2012;138(2):255–9. PubMed PMID: 22904138.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Adriana Maria Knopfelmacher
    • 1
  1. 1.Department of Laboratory MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations